Project description
Cancer patient organoids to guide treatment
Tumours are characterised by great heterogeneity which often impedes drug effectiveness. Therefore, cancer models used in drug development must reflect disease properties in order to recapitulate their drug response. The EU-funded MaCaROM project proposes to use organoids derived from breast cancer patient samples to meet this challenge. Using mass cytometry, scientists will evaluate response of heterogeneous cancer models to different FDA-approved drugs at the single-cell level. Results will provide important information on drug sensitivity and resistance, supporting treatment decisions for improved clinical outcome and increased patient survival.
Fields of science
Programme(s)
Funding Scheme
MSCA-IF-EF-ST - Standard EF











Coordinator
8006 Zurich
Switzerland
See on map